SPRB Spruce Biosciences, Inc.

XNAS 40.49 +0.00% After hours
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

SPRB $40.49 ▲ +0.00%

What changed

Recent filings, trades and moves
Key stats
$78.74
After hours $40.49 +0.00%
52-Week Range
$38.06 – $127.90
YTD
-13.19%
Straddle Price
$6.25
P/C Vol Ratio (Dec 19 expiry)
0.00
Market Cap
$0.1B
Open
$41.87
Day Range
$40.03 – $45.42
Volume
47,624
Prev Close
$40.84
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY2.00
Cost of Equity (CAPM)14.61% (VRP-adj)
WACC13.58%
Volatility Risk Premium-74.6pp (IV − HV30), ERP adj -25bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-101.3%
Book / Price57.5% — banking bias active (P/B is primary)
Debt / Equity0.06
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$46.24 (Market Anchor value)
SMA 20 / Bollinger Mid$44.81
Bollinger Width / SMA2020.1% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: CYRX, KIDS, MYGN, PCRX, XNCR (filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
98%
20-Day Fair Value
≈ by Dec 18, 2026
$40.77
α +0.7% rank 71%
conviction
70%
40-Day Fair Value
≈ by Jan 18, 2027
$41.87
α +3.4% rank 64%
conviction
99%
60-Day Fair Value
≈ by Feb 16, 2027
$42.50
α +5.0% rank 65%
conviction
98%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $48.64 28% median 2.1× · 5 peers
Peer P/S n/a 0% median 3.1× · 5 peers
Market Anchor (SMA50) $46.24 72% stability 49% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-11-19 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
8
List Date
2020-10-09
CIK
0001683553
Last Earnings
Aug 13 · +5.8%
Headquarters
South San Francisco, CA
Homepage
https://www.sprucebiosciences.com

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enz…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan-8.92%-44.66%156.52%23.65%-10.59%-14.50%16.92%
Feb2.70%-14.34%-24.58%45.35%2.42%-29.56%-3.00%
Mar-22.79%-4.74%-2.64%-85.09%-18.51%20.56%-18.87%
Apr0.68%-17.37%-9.25%-13.64%-70.52%-17.56%-21.28%
May-10.74%-10.86%16.27%3.30%-10.66%-10.49%-3.86%
Jun-19.76%19.18%-7.33%-27.58%13.64%6.51%-2.56%
Jul-18.21%8.82%4.17%-2.62%54.71%-19.07%4.63%
Aug-14.01%19.67%-2.17%-7.02%23.85%36.69%9.50%
Sep-21.44%-31.50%1.35%5.00%-0.56%-12.63%-9.96%
Oct-15.90%-18.38%-47.22%14.61%1137.08%3.62%178.97%
Nov-45.91%-0.90%25.00%-0.29%-4.53%-9.11%*-5.96%
Dec85.06%-3.74%96.64%-23.34%4.81%--31.89%
Total-75.78%-72.47%146.79%-85.58%426.77%-48.05%48.61%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $44.53
SMA 50: $45.96
SMA 200: $53.30
Current: $40.34
EMA 12: $43.00
EMA 26: $44.17
MACD: -1.1684 | Signal: -0.4685
BEARISH
ADX (14): 14.33
RANGE
+DI: 22.91
−DI: 18.16

Momentum Oscillators

RSI (14): 40.83
NEUTRAL
Stoch %K: 6.20
Stoch %D: 9.29
Williams %R: -95.13

Volume & Volatility

BB Upper: $49.40
BB Lower: $39.66
NEUTRAL
OBV: 22,727,610
Vol SMA 20: 75,105
Vol ROC: -25.29%
ATR: $3.43
True Range: $5.39
HV 20: 75.4%
HV 30: 74.1%
HV 60: 66.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-11-18T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

Earnings History
5 of 6 under expected move
Avg Expected Move
160.62%
Avg Actual Move
18.09%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-03-13 After-Close 33.16% 84.38% 2.54x Exceeded
2024-08-12 After-Close 173.65% 3.88% 0.02x Within
2024-11-12 After-Close 250.00% 2.78% 0.01x Within
2025-04-01 After-Close 340.63% 9.21% 0.03x Within
2025-11-10 After-Close 5.67% 2.55% 0.45x Within
2026-08-13 unknown — 5.77% — Within

Earnings calendar: this week’s reports with expected vs actual moves →

SPRB Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $6.25
7-DTE Move: $6.25
Days to Exp: — (2025-12-19)

Options Flow · Dec 19 expiry

Call Volume: 3
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 91
Put OI: 0
P/C OI: —
Total OI: 91

ATM Options Pricing

ATM Call: $2.00
ATM Put: $4.25
Call %: 2.5%
Put %: 5.4%

Chain Summary

Chain Volume: 3
Chain OI: 91
Last Updated: 12/19/2025

SPRB Implied Volatility

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much SPRB actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
as of Dec 8 · No data
30 DTE / 10d put —
— pts EXTREME
as of Dec 8 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$6.25Dec 19
Beta Analysis

Risk Metrics

Beta: 1.9686
Alpha: -82.90%
Correlation: 0.3297
R-Squared: 10.9%
Stock Volatility: 83.0%
Market Volatility: 13.9%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

SPRB Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 1,987,630 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

71 filers2,092,072 shares$107.05M value105.25% of float
# Filer Shares Value % of Total % of Float Period
1 AIGH Capital Management LLC 250,000 $12.14M 11.34% 12.58% 2026-09-30
2 ORBIMED ADVISORS LLC 200,000 $10.80M 10.09% 10.06% 2026-06-30
3 BlackRock, Inc. Custodian 192,015 $9.33M 8.71% 9.66% 2026-09-30
4 Millennium Management LLC Custodian 160,981 $8.69M 8.12% 8.10% 2026-06-30
5 AWM Investment Company, Inc. 151,988 $7.38M 6.90% 7.65% 2026-09-30
6 Ikarian Capital, LLC 121,356 $6.55M 6.12% 6.11% 2026-06-30
7 Vanguard Capital Management LLC 119,331 $5.80M 5.42% 6.00% 2026-09-30
8 Alyeska Investment Group, L.P. 81,671 $4.41M 4.12% 4.11% 2026-06-30
9 Geode Capital Management, LLC Custodian 66,757 $3.24M 3.03% 3.36% 2026-09-30
10 Cable Car Capital, LP 60,000 $3.24M 3.03% 3.02% 2026-06-30
11 State Street Corp 59,032 $2.87M 2.68% 2.97% 2026-09-30
12 Citadel Advisors LLC Custodian 51,905 $2.80M 2.62% 2.61% 2026-06-30
13 ADAR1 Capital Management, LLC 51,646 $2.51M 2.34% 2.60% 2026-09-30
14 BOOTHBAY FUND MANAGEMENT, LLC 42,080 $2.27M 2.12% 2.12% 2026-06-30
15 STEMPOINT CAPITAL LP 41,388 $2.23M 2.09% 2.08% 2026-06-30
16 Eversept Partners, LP 40,000 $2.16M 2.02% 2.01% 2026-06-30
17 Carlyle Group Inc. 38,620 $1.88M 1.75% 1.94% 2026-09-30
18 Goldman Sachs Group Inc Custodian 32,348 $1.75M 1.63% 1.63% 2026-06-30
19 DIADEMA PARTNERS LP 30,000 $1.62M 1.51% 1.51% 2026-06-30
20 Point72 Asset Management, L.P. 28,278 $1.53M 1.43% 1.42% 2026-06-30
21 Quinn Opportunity Partners LLC 26,810 $1.30M 1.22% 1.35% 2026-09-30
22 Knott David M Jr 26,085 $1.27M 1.18% 1.31% 2026-09-30
23 ExodusPoint Capital Management, LP 22,000 $1.19M 1.11% 1.11% 2026-06-30
24 Northern Trust Corp Custodian 21,083 $1.14M 1.06% 1.06% 2026-06-30
25 Rosalind Advisors, Inc. 20,000 $1.08M 1.01% 1.01% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

SPRB Insider Trading (Form 4)

Latest: 2026-07-29
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-07-29 Adrian W Quartel Chief Medical Officer Grant (A) +13,000 RSU — EDGAR
2026-07-09 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER Award (A) +266 $4.53 $1.2K EDGAR
2026-05-26 Michael G Grey Executive Chairman Grant (A) +1,700 opt — EDGAR
2026-05-26 Percival Barretto-Ko Director Grant (A) +1,700 opt — EDGAR
2026-05-26 Camilla V Simpson Director Grant (A) +1,700 opt — EDGAR
2026-05-26 Keli Walbert Director Grant (A) +1,700 opt — EDGAR
2026-05-26 Daniel K Spiegelman Director Grant (A) +1,700 opt — EDGAR
2026-03-09 Corwin Dale Hooks Chief Commercial Officer Grant (A) +11,000 RSU — EDGAR
2026-01-21 Douglas Kirk Ways Interim Chief Medical Officer Exer (M) +1,250 — EDGAR
2026-01-05 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER Award (A) +4,690 $4.53 $21.2K EDGAR
2025-12-17 Samir M. Gharib PRESIDENT AND CFO Mixed
Exer +1,009 · Tax −362
+647 $80.67 -$29.2K EDGAR
2025-12-17 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER Mixed
Tax −1,360 · Exer +2,676
+1,316 $80.67 -$109.7K EDGAR
2025-12-15 Keli Walbert Director Grant (A) +3,400 opt — EDGAR
2025-12-15 Percival Barretto-Ko Director Mixed — — EDGAR
2025-12-15 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER Mixed — — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

SPRB Insider Holdings

7 insiders · @ $40.34
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Bali Muralidhar Director 23,900 $964.2K $3.00M 6 2025-07-24
2 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER 19,270 $777.4K $0 14 2026-07-09
3 Samir M. Gharib PRESIDENT AND CFO 8,263 $333.4K $0 18 2025-12-17
4 Ralph William Charlton III CHIEF MEDICAL OFFICER 2,151 $86.8K $0 8 2024-12-20
5 Douglas Kirk Ways Interim Chief Medical Officer 1,250 $50.4K $0 6 2026-01-21
6 Parkman Healthcare Partners LLC 10%+ Owner 1,050 $42.4K -$335 1 2025-10-08
7 Gregory Martinez 10%+ Owner 1,050 $42.4K -$335 1 2025-10-15
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

SPRB Board & Officers

As of SEC filings through Jul 29, 2026

Directors 7

Officers 6

Changes in the last 10 years (48)
Jul 27, 2026Adrian W Quartel became Chief Medical Officer
Mar 9, 2026Corwin Dale Hooks became Chief Commercial Officer
Dec 11, 2025The company announced the departure of Tiba Aynechi from the board in an SEC filing
Dec 11, 2025Keli Walbert became a director
Oct 15, 2025The company announced the departure of Bali Muralidhar from the board in an SEC filing
Oct 15, 2025Parkman Healthcare Partners LLC reported in an SEC filing no longer being a 10% owner
Oct 15, 2025Parkman Healthcare Partners LLC first listed as a 10% owner in an SEC filing
Oct 15, 2025Gregory Martinez reported in an SEC filing no longer being a 10% owner
Oct 8, 2025Parkman Healthcare Partners LLC reported in an SEC filing no longer being a 10% owner
Oct 6, 2025Parkman Healthcare Partners LLC became a 10% owner
Oct 6, 2025Gregory Martinez became a 10% owner
Jul 24, 2025Douglas Kirk Ways first listed as Interim Chief Medical Officer in an SEC filing
Mar 25, 2024Novo Holdings A/S reported in an SEC filing no longer being a 10% owner
May 25, 2023Percival Barretto-Ko became a director
May 22, 2023The company announced the departure of Moghrabi Dina Chaya from the board in an SEC filing
Mar 28, 2022Ralph William Charlton III became Chief Medical Officer
Jan 5, 2022Samir M. Gharib listed as President & CFO (previously Chief Financial Officer) in SEC filings
Jan 1, 2022Javier B. Szwarcberg became a director
Jan 1, 2022Javier B. Szwarcberg became Chief Executive Officer
Jun 23, 2021Douglas Kirk Ways became a director
Not reported recently (5)
  • Ralph William Charlton III · Last reported as Chief Medical Officer in an SEC filing dated Dec 20, 2024
  • Niall O'Donnell · Last reported as a director in an SEC filing dated May 26, 2023
  • Subaweerage Dias · Last reported as Chief Medical Officer in an SEC filing dated Dec 20, 2021
  • Richard King · Last reported as a director in an SEC filing dated Jul 6, 2021
  • Jonas Hansson · Last reported as a director in an SEC filing dated Oct 16, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

SPRB Proposed Insider Sales (Form 144)

Latest: 2024-03-18
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-03-18 Novo Holdings A/S 10% Stockholder 4,810,020 $3.90M 2024-03-18 Morgan Stanley & Co. LLC — EDGAR
2024-03-14 Novo Holdings A/S 10% Stockholder 1,912,316 $9.49M 2024-03-14 Morgan Stanley & Co. LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-09
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-09 Earnings results EDGAR
2026-08-12 Earnings results EDGAR
2026-07-27 Director or officer change EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-09 0001193125-26-452714 EDGAR
2026-08-12 0001193125-26-345876 EDGAR
ETF Holders
19 ETFs hold SPRB
19 shown · $9.69M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $3.1M — 2026-10-31
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.00% $2.8M $75.0B 2026-11-17
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $1.5M — 2026-10-31
4 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $717,969 $13.6B 2026-11-17
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.00% $681,144 — 2026-10-31
6 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.03% $304,849 $1.2B 2026-11-17
7 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.00% $267,355 $13.5B 2026-11-17
8 QQQS Invesco NASDAQ Future Gen 200 ETF Invesco 0.43% $83,085 — 2026-11-17
9 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.01% $80,162 — 2026-10-31
10 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.00% $51,584 $3.1B 2026-11-17
11 RSSL Global X Russell 2000 ETF Global X 0.00% $47,701 — 2026-11-18
12 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.00% $35,071 — 2026-10-31
13 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $15,022 — 2026-11-17
14 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $13,407 — 2026-10-31
15 ITWO ProShares Russell 2000 High Income ETF ProShares 0.00% $5,718 — 2026-11-18
16 URTY ProShares UltraPro Russell2000 ProShares 0.00% $3,921 — 2026-11-18
17 UWM ProShares Ultra Russell2000 ProShares 0.00% $2,736 — 2026-11-18
18 HDG ProShares Hedge Replication ETF ProShares 0.00% $123 — 2026-11-18
19 RB ProShares Russell 2000 Dynamic Buffer ETF ProShares 0.00% $41 — 2026-11-18
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-35.17
TTM Revenue
$0.00
TTM Net Income
$-67.15M
TTM Op. Cash Flow
$-51.07M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$0.00$-24.01M$-8.51$-13.76M
Q2 '262026-06-30$0.00$-16.23M$-6.68$-22.12M
Q1 '262026-03-31$0.00$-12.27M$-8.94$-8.73M
Q4 '252025-12-31$0.00$-14.65M$-11.04$-6.46M
Q3 '252025-09-30$0.00$-8.21M$-14.58$-5.32M
Q2 '252025-06-30$0.00$-2.07M$-3.50$-8.83M
Q1 '252025-03-31—$-14.04M$-23.95$-12.73M
Q4 '242024-12-31$697.00K$-23.56M$-42.72$-20.68M
Q3 '242024-09-30$602.00K$-8.67M$-15.75$-9.22M
Q2 '242024-06-30$1.61M$-9.18M$-16.73$-11.11M
Q1 '242024-03-31$2.00M$-11.62M$-21.00$-14.96M
Q4 '232023-12-31$2.89M$-9.95M$-17.25$-11.21M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-09
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.21
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-101.3%
ROA
-73.0%
Div Yield
0.00%
FCF Yield
-63.45%
Debt/Equity
0.06
Current Ratio
—
Market Cap
$80.48M
as of 2026-11-19

SPRB vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
ATRC AtriCure, Inc. $2.8B 181.4 +13.8% +38.6% 17
XNCR Xencor, Inc. $2.6B — +33.5% +127.9% 43
PCRX Pacira BioSciences, Inc. Common Stock $1.5B 39.2 +3.7% +49.1% 6
SIBN SI-BONE, Inc. Common Stock $1.1B — +14.0% +20.1% 41
CYRX CryoPort, Inc. Common Stock $1.0B — +11.8% +103.5% 11
KIDS OrthoPediatrics Corp. Common Stock $826M — +16.1% +85.2% 38
MYGN Myriad Genetics Inc $530M — −2.6% −9.4% 24
SPRB Spruce Biosciences, Inc. Common Stock $117M — — −55.5% —
QTEX QTREX Quantum Ltd. Ordinary Shares $75M — — +183.6% —
Peer median $1.0B 110.3 +13.8% +67.2% 24

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
531.38K
SI % of Float
22.67%
Days to Cover
6.95
Short Vol Ratio
56.6%
Free Float
2.34M
Float %
81.6%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-11-02